Evolve Private Wealth LLC Takes Position in Emergent Biosolutions Inc. $EBS

Evolve Private Wealth LLC bought a new position in Emergent Biosolutions Inc. (NYSE:EBS) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 65,754 shares of the biopharmaceutical company’s stock, valued at approximately $546,000. Evolve Private Wealth LLC owned 0.13% of Emergent Biosolutions as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of EBS. Baron Wealth Management LLC boosted its stake in Emergent Biosolutions by 40.2% during the first quarter. Baron Wealth Management LLC now owns 15,120 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 4,335 shares during the period. Zacks Investment Management bought a new position in Emergent Biosolutions during the fourth quarter valued at $141,000. Millennium Management LLC raised its stake in shares of Emergent Biosolutions by 205.4% in the fourth quarter. Millennium Management LLC now owns 237,674 shares of the biopharmaceutical company’s stock valued at $2,938,000 after acquiring an additional 159,850 shares during the period. Aristeia Capital L.L.C. purchased a new stake in shares of Emergent Biosolutions in the fourth quarter valued at $345,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Emergent Biosolutions in the 4th quarter worth about $283,000. Institutional investors own 78.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on EBS. Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Wall Street Zen cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. HC Wainwright reduced their price target on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Finally, Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $12.00.

Emergent Biosolutions Stock Performance

Emergent Biosolutions stock opened at $7.95 on Friday. The company has a 50 day moving average price of $8.37 and a 200-day moving average price of $9.76. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29. Emergent Biosolutions Inc. has a fifty-two week low of $5.61 and a fifty-two week high of $14.06. The company has a market capitalization of $410.37 million, a PE ratio of -28.40 and a beta of 2.33.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.46. The company had revenue of $156.10 million for the quarter, compared to analysts’ expectations of $145.00 million. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.

Insider Transactions at Emergent Biosolutions

In other Emergent Biosolutions news, Director Sujata Tyagi Dayal sold 13,761 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $115,592.40. Following the transaction, the director owned 100,563 shares of the company’s stock, valued at approximately $844,729.20. This trade represents a 12.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn C. Zoon sold 17,202 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $144,496.80. Following the completion of the sale, the director owned 79,941 shares of the company’s stock, valued at approximately $671,504.40. This represents a 17.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,925 shares of company stock worth $518,312 over the last quarter. 6.00% of the stock is owned by corporate insiders.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.